Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 13;11:8060. doi: 10.1038/s41598-021-87539-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Linagliptin does not augment Y2R receptor agonist-induced food intake inhibition and weight loss in DIO mice. Linagliptin (3 mg/kg, SC) and long-acting Y2 receptor agonist (PYY analogue, 3 or 30 nmol/kg, SC) was administered once daily for 14 days followed by 6 days of wash-out (no treatment) before study termination. (A) Absolute body weight. (B) Body weight change (relative to day 0). (C) Daily food intake. (D) Cumulative food intake. Horizontal lines denote significant change in body weight compared to vehicle control (p < 0.05, two-way ANOVA with Dunnett’s post-hoc test). Compared to Y2R receptor agonist monotreatment, combined linagliptin and Y2R receptor agonist administration did not promote further changes in body weight and daily food intake (p > 0.05, two-way ANOVA with Dunnett’s post-hoc test). Compensatory overeating was observed following treatment cessation.